A ketone body fuels a new era for engineered cancer immunotherapy
A pivotal study published in *Cell* reveals a direct metabolic strategy to enhance adoptive cancer immunotherapy. Researchers discovered that β-hydroxybutyrate (BHB), the primary ketone body produced during a ketogenic diet, acts as a potent metabolic reprogramming agent for CAR T cells. When supplemented with BHB, these engineered immune cells exhibited superior proliferation, robust cytokine production, and significantly improved tumor control in models of cancer. This research identifies a clear, practical link between cellular metabolism and therapeutic efficacy, suggesting that simple nutritional or pharmacological supplementation could be leveraged to boost the clinical performance of cutting-edge cell therapies.
Study Significance: For professionals in genetics and gene therapy, this work bridges functional genomics and clinical application by identifying a metabolomic pathway that can be targeted to optimize engineered cell function. It provides a tangible, translatable strategy to overcome a key limitation in adoptive immunotherapy—T cell exhaustion and metabolic insufficiency—potentially improving patient outcomes in oncology. This finding underscores the importance of integrating multi-omics insights, where understanding the interplay between genetic engineering and cellular metabolism is crucial for advancing next-generation therapeutics.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
